

Hoxie & Associates LLC

RECEIVED
CENTRAL FAX CENTER

OCT 30 2009

FAX COVER SHEET

Date: 10/30/09

To: Examiner ~~Rob~~ Hope Robinson

Fax Number: 1-571-273-8300 Art Unit

From: Jay Pattumudi 1652

Re:

Message:

Re proposed amendments
to: Claims for
10/567, 763

Total pages sent (including cover sheet): 3

The information contained in this facsimile/electronic message is proprietary and confidential and is only and exclusively addressed to the named recipient(s). Any use, copying or distribution of the above-referenced information by any unintended recipient may be illicit and result in damage, harm and loss to the sender and/or to the intended recipient(s). If you have received this message in error, please immediately notify us.

Note: I ~~will~~ have a doctor's
appointment today at
10:10 am. If I can't
reach you ~~in~~ the morning,
please try to reach me
in late afternoon (around
2pm or so).

75 Main Street | Suite 301 | Millburn, NJ 07041
Telephone: (973) 912-5232 | Fax: (973) 912-5236 | www.hoxiepatent.com

OCT 30 2009

Re: Proposed amendments to 10/567,763

Examiner Robinson, from your fax, I think you are deleting the limitations of claim 9 reciting, "ii) an amino acid sequence derivable from SEQ ID NO: [[2]] 16 by addition, deletion, insertion, or a conservative substitution of one or more amino acids in the amino acid sequence of SEQ ID NO: [[2]] 16, wherein the conservative substitution is selected from the following substitution: Ala to Val/Leu/Ile, Arg to Lys/Gln/Asn, Asn to Gln/His/Lys/Arg, Asp to Glu, Cys to Ser, Gln to Asn, Glu to Asp, Gly to Pro/Ala, His to Asn/Gln/Lys/Arg, Ile to Leu/Val/Met/Ala/Phe/nor Leu, Lys to Arg/Gln/Asn, Met to Leu/Phe/Ile, Phe to Leu/Val/Ile/Ala/Tyr, Pro to Ala, Ser to Thr, Thr to Ser, Trp to Tyr/Phe, Tyr to Trp/Phe/Thr/Ser, and Val to Ile/Leu/Met/Phe/Ala/nor Leu."

Below are my proposed amendments:

9. An isolated polypeptide having L-sorbose dehydrogenase activity comprising:
(i) SEQ ID NO: [[2]] 16; **or an amino acid sequence derivable from SEQ ID 16, wherein the amino acid sequence is encoded by a polynucleotide having a homology of at least 90% with SEQ ID NO: 1.** [(ii)
an amino acid sequence derivable from SEQ ID NO: [[2]] 16 by addition, deletion, insertion, or a conservative substitution of one or more amino acids in the amino acid sequence of SEQ ID NO: [[2]] 16, wherein the conservative substitution is selected from the following substitution: Ala to Val/Leu/Ile, Arg to Lys/Gln/Asn, Asn to Gln/His/Lys/Arg, Asp to Glu, Cys to Ser, Gln to Asn, Glu to Asp, Gly to Pro/Ala, His to Asn/Gln/Lys/Arg, Ile to Leu/Val/Met/Ala/Phe/nor Leu, Lys to Arg/Gln/Asn, Met to Leu/Phe/Ile, Phe to Leu/Val/Ile/Ala/Tyr, Pro to Ala, Ser to Thr, Thr to Ser, Trp to Tyr/Phe, Tyr to Trp/Phe/Thr/Ser, and Val to Ile/Leu/Met/Phe/Ala/nor Leu.]]
[Brackets: your proposed amendments, bold lines are my proposed amendments.]

10. (Currently amended) The isolated polypeptide according to claim 9, wherein the isolated polypeptide sequence is SEQ ID NO: [[2]] 16.

(Note: Kept my amendment.)

~~An isolated polypeptide consisting of SEQ ID NO: 16, wherein said polypeptide has L-sorbose dehydrogenase activity.~~

11. (Currently amended) The polypeptide according to claim 9, wherein the amino acid sequence is derivable from SEQ ID NO: [[2]] 16 by conservative substitution.

[Note: Kept my amendment.]

43. (New) The polypeptide according to claim 11, wherein the the conservative substitution is selected from the following substitution: Ala to Val/Leu/Ile, Arg to Lys/Gln/Asn, Asn to Gln/His/Lys/Arg, Asp to Glu, Cys to Ser, Gln to Asn, Glu to Asp, Gly to Pro/Ala, His to Asn/Gln/Lys/Arg, Ile to Leu/Val/Met/Ala/Phe/nor Leu, Lys to Arg/Gln/Asn, Met to Leu/Phe/Ile, Phe to Leu/Val/Ile/Ala/Tyr, Pro to Ala, Ser to Thr, Thr to Ser, Trp to Tyr/Phe, Tyr to Trp/Phe/Thr/Ser, and Val to Ile/Leu/Met/Phe/Ala/nor Leu. (New claim reciting the limitations of your earlier proposed amendment to claim 9.)